NASDAQ, TSX: NVCN VANCOUVER, CA, and BERLIN, DE, November 26, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...
Read More- Educational events featuring the Reducer hosted in Germany and Italy - VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, November 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, November 19, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that...
Read MoreNASDAQ, TSX: NVCN VANCOUVER, and MAINZ, Germany, November 12, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read More®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 06, 2019 -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of...
Read MoreNASDAQ, TSX: NVCN Recent Highlights Delivered continued revenue growth for Neovasc ReducerTM (“Reducer”) Reducer added to the European Society of Cardiology Practice Guidelines for the treatment of refractory angina Reducer featured at the 40th Annual National Congress of the Italian Society of Interventional Cardiology Announced Norman...
Read More®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 06, 2019 -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that Fred...
Read More®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 05, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...
Read More